These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 3882058)

  • 41. Neomycin and plasma lipoproteins in type II hyperlipoproteinemia.
    Hoeg JM; Schaefer EJ; Romano CA; Bou E; Pikus AM; Zech LA; Bailey KR; Gregg RE; Wilson PW; Sprecher DL
    Clin Pharmacol Ther; 1984 Oct; 36(4):555-65. PubMed ID: 6383687
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effect of bezafibrate on the high-density lipoprotein subfractions HDL2 and HDL3 in primary hyperlipoproteinemia type IV.
    Schwandt P; Weisweiler P
    Artery; 1980; 7(6):464-70. PubMed ID: 7236016
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effect of bezafibrate and colestyramine in patients with primary hypercholesterolemia.
    Steinhagen-Thiessen E; Müller S; Holler HD; Lang PD
    Arzneimittelforschung; 1987 Jun; 37(6):726-8. PubMed ID: 3311054
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Combined bezafibrate and simvastatin treatment for mixed hyperlipidaemia.
    Kehely A; MacMahon M; Barbir M; Wray R; Hunt BJ; Prescott RJ; Thompson GR
    QJM; 1995 Jun; 88(6):421-7. PubMed ID: 7648234
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Treatment with probucol of children with familial hypercholesterolaemia.
    Sanjurjo P; Martul P; Sasieta M; Lafuente P; Ariza F; Cabeza I
    Acta Paediatr Scand; 1988 Jan; 77(1):132-5. PubMed ID: 3285634
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effects of bezafibrate on HDL2/HDL3 ratio in postmenopausal hypertriglyceridemic women.
    Ushiroyama T; Sakuma K; Nosaka S
    J Cardiovasc Pharmacol Ther; 2006 Jun; 11(2):142-8. PubMed ID: 16891292
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Acifran: a double-blind, randomized, placebo-controlled efficacy study in type IIa hyperlipoproteinemic patients.
    LaRosa JC; Miller VT; Edwards KD; DeBovis MR; Stoy DB
    Artery; 1987; 14(6):338-50. PubMed ID: 3314798
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Coronary artery disease and haemostatic variables in heterozygous familial hypercholesterolaemia.
    Sugrue DD; Trayner I; Thompson GR; Vere VJ; Dimeson J; Stirling Y; Meade TW
    Br Heart J; 1985 Mar; 53(3):265-8. PubMed ID: 3970784
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Effect of bezafibrate on disorders of lipid metabolism].
    Stryjek-Kamińska D; Ilińska-Debniak K; Bartosiewicz W; Szczepanik Z
    Pol Tyg Lek; 1983 Dec; 38(50):1567-71. PubMed ID: 6379618
    [No Abstract]   [Full Text] [Related]  

  • 50. Clinical experience with bezafibrate.
    Schubotz R; Schneider J; Hausmann L; Mühlfellner G; Mühlfellner O; Kaffarnik H
    Artery; 1980; 8(6):553-9. PubMed ID: 7259534
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effects of successive dose increases of policosanol on the lipid profile of patients with type II hypercholesterolaemia and tolerability to treatment.
    Pons P; Rodríguez M; Robaina C; Illnait J; Más R; Fernández L; Fernández JC
    Int J Clin Pharmacol Res; 1994; 14(1):27-33. PubMed ID: 7927958
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Simvastatin but not bezafibrate decreases plasma lipoprotein-associated phospholipase A₂ mass in type 2 diabetes mellitus: relevance of high sensitive C-reactive protein, lipoprotein profile and low-density lipoprotein (LDL) electronegativity.
    Constantinides A; de Vries R; van Leeuwen JJ; Gautier T; van Pelt LJ; Tselepis AD; Lagrost L; Dullaart RP
    Eur J Intern Med; 2012 Oct; 23(7):633-8. PubMed ID: 22902096
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effects of addition of policosanol to omega-3 fatty acid therapy on the lipid profile of patients with type II hypercholesterolaemia.
    Castaño G; Fernández L; Mas R; Illnait J; Gámez R; Mendoza S; Mesa M; Fernández J
    Drugs R D; 2005; 6(4):207-19. PubMed ID: 16050054
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Dietary management of patients with familial hypercholesterolaemia treated with simvastatin.
    Chisholm A; Mann J; Sutherland W; Williams S; Ball M
    Q J Med; 1992; 85(307-308):825-31. PubMed ID: 1484945
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Double-blind cross-over study of the effect of sultosilic acid piperazine salt (A-585) and bezafibrate in primary hyperlipoproteinemia.
    Vinazzer H; Farine JC
    Atherosclerosis; 1983 Nov; 49(2):109-18. PubMed ID: 6686778
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A cross-over controlled study on beclobrate versus bezafibrate in the treatment of type IIb hyperlipoproteinaemia.
    Avogaro P; Bittolo Bon G; Cazzolato G; Soldan S; Bufalino L
    Drugs Exp Clin Res; 1989; 15(6-7):325-33. PubMed ID: 2686956
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The effect of a slow release formulation of bezafibrate on lipids, glucose homeostasis, platelets and fibrinogen in type II diabetics: a pilot study.
    Mathur S; Barradas MA; Mikhailidis DP; Dandona P
    Diabetes Res; 1990 Jul; 14(3):133-8. PubMed ID: 2132185
    [TBL] [Abstract][Full Text] [Related]  

  • 58. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial.
    Raal FJ; Stein EA; Dufour R; Turner T; Civeira F; Burgess L; Langslet G; Scott R; Olsson AG; Sullivan D; Hovingh GK; Cariou B; Gouni-Berthold I; Somaratne R; Bridges I; Scott R; Wasserman SM; Gaudet D;
    Lancet; 2015 Jan; 385(9965):331-40. PubMed ID: 25282519
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial.
    Raal FJ; Honarpour N; Blom DJ; Hovingh GK; Xu F; Scott R; Wasserman SM; Stein EA;
    Lancet; 2015 Jan; 385(9965):341-50. PubMed ID: 25282520
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The effect of cyclandelate on cholesterol metabolism in patients with familial hypercholesterolaemia.
    Gevers Leuven JA; vd Voort H; Kempen HJ; de Wit E; Havekes L
    Drugs; 1987; 33 Suppl 2():131-5. PubMed ID: 3304952
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.